New app aims to simplify diabetes management for insulin users

NCT ID NCT07282639

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a smartphone app called DailyDose that gives personalized advice on insulin doses and carbohydrate intake for people with type 1 diabetes who use multiple daily injections. The app uses data from continuous glucose monitors and insulin pens. Researchers want to see if using the app for 24 weeks can lower blood sugar levels (HbA1c). About 99 adults will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
DailyDose smartphone app (decision support tool)
What this could lead to
If it works, this app could help people with type 1 diabetes better manage their blood sugar and reduce the risk of complications.
What could go wrong
This is a small, early-stage study (99 people) testing an app, not a new drug. The app may not work for everyone, and results may not apply to all people with diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES (T1D) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Barbara Davis Center

    Aurora, Colorado, 80045, United States

  • Joslin Diabetes Center, Harvard School of Medicine

    Boston, Massachusetts, 02215, United States

  • Mount Sinai School of Medicine

    New York, New York, 10029, United States

  • Oregon Health & Science University , Portland

    Portland, Oregon, 97239, United States

  • University of California, San Diego

    La Jolla, California, 92037, United States

  • University of Southern California

    Los Angeles, California, 90022, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.